# FLExAbility Sensor Enabled Substrate Targeted Ablation for the Reduction of VT Study

Study · id `cardio:ct-nct03490201` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03490201](<https://clinicaltrials.gov/study/NCT03490201>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03490201

Browse, organ or system: Heart  
Browse, condition area: Heart rhythm problems  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 592 participants.

## Technical summary

Registry record NCT03490201. Randomized; single masking; primary purpose treatment. Start 2018-06-01 (actual); primary completion 2024-04-11 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 592 participants (enrolled count; ClinicalTrials.gov record NCT03490201, source copy `cardio:ctgov-nct03490201-2025-01-08`, retrieved 2026-10-26)
- Started: 2018-06-01 (actual) (ClinicalTrials.gov record NCT03490201, source copy `cardio:ctgov-nct03490201-2025-01-08`, retrieved 2026-10-26)
- Primary completion: 2024-04-11 (actual) (ClinicalTrials.gov record NCT03490201, source copy `cardio:ctgov-nct03490201-2025-01-08`, retrieved 2026-10-26)
- Completion: 2024-04-11 (actual) (ClinicalTrials.gov record NCT03490201, source copy `cardio:ctgov-nct03490201-2025-01-08`, retrieved 2026-10-26)
- Countries: United States; Australia; Czechia; France; Germany; Italy; Spain; United Kingdom (ClinicalTrials.gov record NCT03490201, source copy `cardio:ctgov-nct03490201-2025-01-08`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03490201-2025-01-08`, retrieved 2026-10-26)

## The registry's words

- Brief title: FLExAbility Sensor Enabled Substrate Targeted Ablation for the Reduction of VT Study
- Acronym: LESS-VT
- Condition: Ventricular Tachycardia
- Intervention (Device): Market Approved RF Ablation System
- Intervention (Device): FlexAbility SE Ablation Catheter
- Lead sponsor: Abbott Medical Devices
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Ventricular tachycardia (`cardio:ventricular-tachycardia`)
- Registry lists this organization as the lead sponsor: Abbott (`cardio:abbott`)

## Provenance

Content hash: a360bd3a55b5b42de584a3aea3f3c8eb09c725b9c323effdb72c150f1aceb94a
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
